Compact Synthesizers Let Small Labs Make Their Own Genes

Molecular biologists and geneticists depend on the ability of DNA synthesizers to produce man-made oligonucleotides (oligos) of defined sequence for a variety of genetic studies, from the isolation of genes not clonable by other techniques to the diagnosis of mutations responsible for human genetic diseases. Research facilities specializing in recombinant DNA techniques typically own or have access to high-throughput DNA synthesizers, which are capable of simultaneously manufacturing up to 15 m

Written byCarole Gan
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Molecular biologists and geneticists depend on the ability of DNA synthesizers to produce man-made oligonucleotides (oligos) of defined sequence for a variety of genetic studies, from the isolation of genes not clonable by other techniques to the diagnosis of mutations responsible for human genetic diseases. Research facilities specializing in recombinant DNA techniques typically own or have access to high-throughput DNA synthesizers, which are capable of simultaneously manufacturing up to 15 micromoles (one millionth of a mole) of four independently programmed DNA or RNA sequences.

Individual laboratories, however, do not need the full range of capabilities of these high-throughput instruments, and often cannot afford their cost. As a result, these labs have traditionally relied on the services of a central DNA synthesis facility or have purchased oligos on a custom basis from commercial suppliers.

But in recent years a new class of low-cost, high-speed DNA synthesizers has been developed. These new ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies